Literature DB >> 23970017

Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA.

A Trebouet1, T Marchand, R Lemal, E Gyan, F Broussais-Guillaumot, Y Guillermin, H Monjanel, G Salles, S Le Gouill, P Godmer, C Fruchart, G Damaj, P Feugier, C Thieblemont, M Maynadié, A Monnereau, X Troussard, D Rossille, T Lamy, R Houot.   

Abstract

BACKGROUND: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population. PATIENTS AND METHODS: We retrospectively analyzed 234 patients diagnosed with lymphoma at the age of 90 years or older (90+) between 1990 and 2012 to describe their characteristics, management, outcomes and prognostic factors.
RESULTS: The median age was 92 years; 88% were B-cell lymphomas consisting mainly in diffuse large B-cell lymphoma. The median overall survival (OS) was 7.2 months (range, 0-92 months) for the 227 patients with non-Hodgkin Lymphoma (NHL), with a significant difference between aggressive and indolent NHL (5.2 months versus 19.4 months, respectively). We further analyzed 166 NHL patients for whom detailed characteristics were available. Among these patients, 63.5% received a treatment, either local (7.5%) or systemic (56%). Lymphoma was reported as the main cause of death (40%). Treatment administration was associated with improved OS in patients with aggressive (P < 0.001) but not indolent NHL (P = 0.96). In patients with aggressive NHL, hypoalbuminemia appeared as a strong and independent negative prognostic factor.
CONCLUSIONS: The median OS is short in 90+ patients diagnosed with lymphoma but some patients experience prolonged survival. Lymphoma represents the main cause of death in these patients. Treatment may improve survival of selected patients with aggressive but not indolent NHL. Management of these patients may be guided by prognostic factors identified in this study, notably serum albumin.

Entities:  

Keywords:  aged 80 and over; comorbidity; lymphoma; palliative care

Mesh:

Substances:

Year:  2013        PMID: 23970017     DOI: 10.1093/annonc/mdt282

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  11 in total

1.  Survival outcomes in the very elderly with DLBCL prior to and after the introduction of rituximab: a US population-based study.

Authors:  Upama Giri; Michael G Martin
Journal:  Blood Adv       Date:  2017-04-06

Review 2.  Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.

Authors:  Abhijeet Kumar; Muhammad Asad Fraz; Muhammad Usman; Saad Ullah Malik; Awais Ijaz; Ceren Durer; Seren Durer; Muhammad Junaid Tariq; Ali Younas Khan; Anum Qureshi; Warda Faridi; Aboo Nasar; Faiz Anwer
Journal:  Curr Treat Options Oncol       Date:  2018-09-01

3.  Cancer treatment in the extreme elderly: case study of a 100-year-old lymphoma patient.

Authors:  Peter J Gilbar; Howard Mutsando; Joshua P Richmond; Ronald B Middleton
Journal:  Int J Hematol Oncol       Date:  2016-08-19

Review 4.  Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review.

Authors:  Yun Hwa Jung; In Sook Woo; Chi Wha Han
Journal:  Korean J Intern Med       Date:  2015-08-27       Impact factor: 2.884

Review 5.  Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.

Authors:  Jacqueline C Barrientos
Journal:  Onco Targets Ther       Date:  2016-05-18       Impact factor: 4.147

Review 6.  Management of aggressive lymphoma in very elderly patients.

Authors:  Catherine Thieblemont; Sophie Bernard; Thierry Molina
Journal:  Hematol Oncol       Date:  2017-06       Impact factor: 5.271

7.  Lymphomas diagnosed in an internal medicine department compared to lymphomas diagnosed in other departments: Clinical and outcome differences.

Authors:  Benoit Pernot; Emmanuel Gyan; François Maillot; Penelope Hodges; Marjan Ertault; Nicole Ferreira-Maldent
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

8.  Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics.

Authors:  Jozette J C Stienen; Rosella P M G Hermens; Lianne Wennekes; Saskia A M van de Schans; Richard W M van der Maazen; Helena M Dekker; Janine Liefers; Johan H J M van Krieken; Nicole M A Blijlevens; Petronella B Ottevanger
Journal:  BMC Cancer       Date:  2015-08-08       Impact factor: 4.430

9.  Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Authors:  Aurélie Cabannes-Hamy; Frederic Peyrade; Fabrice Jardin; Jean-François Emile; Vincent Delwail; Nicolas Mounier; Corinne Haioun; Aurore Perrot; Olivier Fitoussi; Diane Lara; Richard Delarue; Marc André; Fritz Offner; Hervé Ghesquières; Laurent Pascal; Carole Soussain; Julien Lazarovici; Jean-Marc Schiano; Philippe Gaulard; Hervé Tilly; Catherine Thieblemont
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

10.  Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions.

Authors:  Chelsea C Pinnix; Therese Y Andraos; Bouthaina Dabaja; Sarah Milgrom; Grace Smith; Dai Chihara; Andrea Ng; Luis E Fayad; Yasuhiro Oki; Sattva Neelapu; Jason Westin; M Alma Rodriguez; Loretta J Nastoupil
Journal:  Adv Radiat Oncol       Date:  2017-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.